The current consensus view supports a role for HIF2α in the development of PAH, most probably through influencing multiple signalling pathways across pulmonary vascular beds leading to the progressive loss of vascular identity/plasticity/homeostasis that drives remodelling and increases vessel resistance. The gene discussed is EPAS1; the disease is pulmonary arterial hypertension.